An internal analysis conducted by Johnson & Johnson in 2011 not long
after it recalled a troubled hip implant estimated that the all-metal device
would fail within five years in nearly 40 percent of patients who received it,
newly disclosed court records show.
Johnson & Johnson never released those projections for the device,
the Articular Surface Replacement, or A.S.R., which the company recalled in
mid-2010. But at the same time that the medical products giant was performing
that analysis, it was publicly playing down similar findings from a British
implant registry about the device’s early failure rate.
The company’s analysis also suggests that the implant is likely to
fail prematurely over the next few years in thousands more patients in addition
to those who have already had painful and costly procedures to replace it.
No comments:
Post a Comment